Discordant HER2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.

Charlotta Hedner; Lena Tran; David Borg; Björn Nodin; Karin Jirström; Jakob Eberhard

doi:10.1111/his.12744

Discordant HER2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.

Charlotta Hedner, Lena Tran, David Borg, Björn Nodin, Karin Jirström, Jakob Eberhard

Tumor microenvironment

Research output: Contribution to journal › Article › peer-review

Abstract

Targeted therapy with trastuzumab has proven to be effective for patients with gastric cancer overexpressing the human epidermal growth factor receptor 2 (HER2). Further studies are needed to determine the best method for assessment of HER2 overexpression. Moreover, the prognostic value of HER2 overexpression, including the significance of tumour heterogeneity, remains unclear.

Original language	English
Journal	Histopathology
Early online date	2015 May 27
DOIs	https://doi.org/10.1111/his.12744
Publication status	Published - 2015

Subject classification (UKÄ)

Cell and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/his.12744

http://www.ncbi.nlm.nih.gov/pubmed/26016514?dopt=Abstract

1 Doctoral Thesis (compilation)

Prognostic biomarkers in upper gastrointestinal adenocarcinoma
HEDNER, C., 2016, Lund: Lund University: Faculty of Medicine. 78 p.
Research output: Thesis › Doctoral Thesis (compilation)

Open Access
File

Cite this

@article{2925b5f360804594a782ed02f25df724,

title = "Discordant HER2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.",

abstract = "Targeted therapy with trastuzumab has proven to be effective for patients with gastric cancer overexpressing the human epidermal growth factor receptor 2 (HER2). Further studies are needed to determine the best method for assessment of HER2 overexpression. Moreover, the prognostic value of HER2 overexpression, including the significance of tumour heterogeneity, remains unclear.",

author = "Charlotta Hedner and Lena Tran and David Borg and Bj{\"o}rn Nodin and Karin Jirstr{\"o}m and Jakob Eberhard",

year = "2015",

doi = "10.1111/his.12744",

language = "English",

journal = "Histopathology",

issn = "0309-0167",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Discordant HER2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.

AU - Hedner, Charlotta

AU - Tran, Lena

AU - Borg, David

AU - Nodin, Björn

AU - Jirström, Karin

AU - Eberhard, Jakob

PY - 2015

Y1 - 2015

N2 - Targeted therapy with trastuzumab has proven to be effective for patients with gastric cancer overexpressing the human epidermal growth factor receptor 2 (HER2). Further studies are needed to determine the best method for assessment of HER2 overexpression. Moreover, the prognostic value of HER2 overexpression, including the significance of tumour heterogeneity, remains unclear.

AB - Targeted therapy with trastuzumab has proven to be effective for patients with gastric cancer overexpressing the human epidermal growth factor receptor 2 (HER2). Further studies are needed to determine the best method for assessment of HER2 overexpression. Moreover, the prognostic value of HER2 overexpression, including the significance of tumour heterogeneity, remains unclear.

U2 - 10.1111/his.12744

DO - 10.1111/his.12744

M3 - Article

C2 - 26016514

SN - 0309-0167

JO - Histopathology

JF - Histopathology

ER -

Discordant HER2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Research output

Prognostic biomarkers in upper gastrointestinal adenocarcinoma

Cite this